Ovarian Neoplasms (Ovarian Cancer)

Subscribe to Selected New Research on Ovarian Neoplasms

13751 relevant articles (966 outcomes, 3161 trials/studies) found for this Disease

Description: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Also Known As:

Ovarian Cancer; Cancer, Ovarian; Ovarian Neoplasm; Cancer of the Ovary; Neoplasms, Ovarian; Ovary Cancer; Ovary Neoplasms; Cancer, Ovary; Cancers, Ovarian; Cancers, Ovary; Neoplasm, Ovarian; Neoplasm, Ovary; Neoplasms, Ovary; Ovarian Cancers; Ovary Cancers; Ovary Neoplasm; Cancer of Ovary

Relationship Network

Disease Context: Research Results

Neoplasms: 415397

Neoplasms by Site: 1

Endocrine Gland Neoplasms: 37

Ovarian Neoplasms: 13751

Granulosa Cell Tumor: 314

Sertoli-Leydig Cell Tumor: 84

Thecoma: 83

Luteoma: 49

Meigs Syndrome: 29

Endocrine System Diseases: 398

Endocrine Gland Neoplasms: 37

Ovarian Neoplasms: 13751

Granulosa Cell Tumor: 314

Sertoli-Leydig Cell Tumor: 84

Thecoma: 83

Luteoma: 49

Meigs Syndrome: 29

Gonadal Disorders: 19

Ovarian Diseases: 449

Ovarian Neoplasms: 13751

Endometrioid Carcinoma: 454

Granulosa Cell Tumor: 314

Sertoli-Leydig Cell Tumor: 84

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoma (Carcinomatosis)
3.	Breast Neoplasms (Breast Cancer)
4.	Ascites
5.	Neoplasm Metastasis (Metastasis)

Experts

1.	Markman, Maurie: 46 articles (04/2008 - 02/2002)
2.	Ma, Ding: 30 articles (10/2008 - 11/2002)
3.	Sood, Anil K: 21 articles (10/2008 - 10/2002)
4.	Katsaros, Dionyssios: 21 articles (05/2008 - 02/2002)
5.	Diamandis, Eleftherios P: 21 articles (12/2007 - 04/2002)
6.	Scambia, G: 21 articles (08/2007 - 01/2000)
7.	Scambia, Giovanni: 20 articles (06/2008 - 01/2002)
8.	Sehouli, Jalid: 19 articles (08/2008 - 05/2002)
9.	Mok, Samuel C: 18 articles (09/2008 - 04/2002)
10.	Berchuck, Andrew: 18 articles (07/2008 - 02/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ovarian Neoplasms:

1.	Paclitaxel (Taxol)FDA LinkGeneric 02/01/2009 - "Paclitaxel is used in the first line treatment of ovarian cancer, but acquired resistance represents the most important clinical problem and a major obstacle to a successful therapy. " 09/01/2007 - "Both times, the paclitaxel dramatically improved the ovarian cancer. " 03/01/2004 - "Paclitaxel (PTX) is a potent anti-neoplastic agent that is highly effective in treating ovarian cancer. " 04/01/1996 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. " 02/15/1995 - "Taxol has been called the best new anticancer agent developed from natural products, showing particular efficacy against ovarian cancer. " Order ALL the reference details at left...
2.	Cisplatin (Platino)FDA LinkGeneric 12/01/2006 - "The markedly improved survival data resulting from a phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCI Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on intraperitoneal therapy in January, 2006, in San Diego, California. " 01/01/2004 - "Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. " 12/01/1985 - "These results demonstrate that the cisplatin dose is an important factor in achieving improved results in the treatment of ovarian cancer." 01/01/2001 - "Phase III trials employing intraperitoneal cisplatin as initial treatment of small volume advanced ovarian cancer have demonstrated that regional therapy results in a modest, but statistically significant, improvement in both progression-free and overall survival compared to intravenous cisplatin. " 07/01/2002 - "Although cisplatin derivatives are first-line chemotherapeutic agents for the treatment of epithelial ovarian cancer, chemoresistance remains a major hurdle to successful therapy and the molecular mechanisms involved are poorly understood. " Order ALL the reference details at left...
3.	PlatinumIBA 01/01/2006 - "By contrast, most studies indicate that women developing a BRCA1/2-related ovarian cancer have an improved survival compared with non-carriers, particularly if they receive platinum-based therapy. " 01/01/1993 - "Platinum-containing regimens are very effective in the primary treatment of ovarian cancer. " 08/01/2006 - "RESULTS: Using costs alone, BSC was the only definitive cost-effective treatment for platinum-resistant recurrent ovarian cancer patients, and second-line monotherapy was a reasonable cost-effective strategy with an incremental cost-effectiveness ratio (ICER) of 64,104 dollars. " 03/01/2000 - "In conclusion, the PEC combination, an anthracycline-containing platinum-based regimen, proved to be effective in advanced ovarian cancer, in terms of response rate and overall survival. " 12/01/2001 - "Recent phase II clinical trials in relapsed ovarian cancer have demonstrated efficacy in patients with platinum-refractory disease (defined as progression on or relapse within 6 months of previous therapy). " Order ALL the reference details at left...
4.	Carboplatin (JM8)FDA LinkGeneric 11/01/1999 - "AIM: The aim of this study was to evaluate the efficacy of 51Cr-EDTA clearance to tailor the carboplatin dose in two different therapeutic regimens of advanced epithelial ovarian cancer. " 11/01/1999 - "Efficacy of 51Cr-EDTA clearance to tailor a carboplatin therapeutic regimen in ovarian cancer patients." 07/01/1997 - "CONCLUSIONS: Carboplatin proved to be effective in patients with optimally debulked ovarian cancer. " 09/01/1995 - "CONCLUSION: CSA is effective in reversing CBDCA resistance in A2780 ovarian cancer cells. " 02/01/2009 - "Based on promising results of a pilot study, we initiated a phase II study with WBH and carboplatin in pretreated patients with advanced ovarian cancer to investigate the toxicity and efficacy of WBH in combination with carboplatin. " Order ALL the reference details at left...
5.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/01/1976 - "In about 50% of primarily inoperable stage 3 ovarian cancers, the random treatment with cyclophosphamide (Endoxan) results in a clinical remission. " 06/01/1990 - "Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer." 03/01/1982 - "In a small pilot therapy-trial there was no difference in the survival rate between patients with stage III and IV ovarian cancer treated with cyclophosphamide plus BCG and those who received only cyclophosphamide. " 09/15/2003 - "More than 65% of women with ovarian cancer were given cyclophosphamide in 1991 compared with about 14% in 1996. " 05/01/1993 - "Sixty-six patients with ovarian cancer were treated with low-dose consecutive CP (LDC-CP) consisting of cyclophosphamide (CPM: 500 mg/m2, day 1) and CDDP (10 mg/m2, days 1-7). " Order ALL the reference details at left...
6.	Topotecan (Hycamtin)FDA Link 03/01/2009 - "Conclusion: The peer-reviewed literature reports that topotecan is an effective, well tolerated treatment option for relapsed ovarian cancer." 03/01/2005 - "Intraperitoneal administration of topotecan as consolidation therapy in patients with ovarian cancer has shown promising results. " 03/01/1996 - "Trial of topotecan as first-line treatment for ovarian cancer announced." 08/01/2005 - "Weekly topotecan may be an appropriate treatment option for patients with recurrent ovarian cancer, especially heavily pretreated patients who might require dosing schedules with improved tolerability." 12/01/2004 - "OBJECTIVE: To retrospectively investigate the safety and efficacy of weekly topotecan in heavily pretreated patients with ovarian cancer. " Order ALL the reference details at left...
7.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/01/1998 - "OBJECTIVE: Although doxorubicin is not currently popular as a primary agent in ovarian cancer, overviews of previous studies suggest that the inclusion of doxorubicin may have improved outcome. " 11/01/2009 - "This drug in combination with doxil has shown to improve outcome in relapsed ovarian cancer, compared with doxil alone. " 05/01/2007 - "The resultant nanosized systems improved the uptake and cytotoxicity of doxorubicin in the ovarian cancer cells, OVCAR-3, with statistical significance. " 01/01/2004 - "The aim of this study was to investigate the reversal of adriamycin resistance in human ovarian cancer cells by ultrasound exposure from perspectives of apoptosis and mdr1 gene. " 12/01/2001 - "Caelyx: phase II studies in ovarian cancer." Order ALL the reference details at left...
8.	gemcitabine FDA Link 11/13/2005 - "Some chemotherapeutic combinations with gemcitabine for the first line treatment of ovarian cancers are also known and they were found to be superior to the multi-line treatments (81.6 +/- 17.9% complete remission on average with the former). " 01/01/2003 - "Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients." 09/01/2008 - "BACKGROUND: Our study aimed to investigate if p38-MAPK determined in primary ovarian cancer can serve as a predictive marker for sensitivity to gemcitabine treatment in recurrent disease. " 08/01/2008 - "Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer." 04/01/2006 - "The role of gemcitabine in first-line advanced ovarian cancer will become much clearer once the results from the various phase III trials are published." Order ALL the reference details at left...
9.	docetaxel (Taxotere)FDA Link 07/01/2009 - "Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study." 12/01/2000 - "BACKGROUND: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in Japanese patients with advanced ovarian cancer. " 01/01/1999 - "Japanese Docetaxel Ovarian Cancer Study Group." 11/01/1997 - "Docetaxel (Taxotere) has been studied at a dose of 100 mg/m2 i.v. as a one hour infusion every 3 weeks, in four phase II trials in patients with extensively pretreated ovarian cancer. " 11/01/1997 - "Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview." Order ALL the reference details at left...
10.	AntigensIBA 05/01/1992 - "The combined assay of serum S-Tn and CA 125 antigens gave positive results in 38 of 48 (79.2%) patients with ovarian cancers; most of the negative findings were obtained in Stage I disease. " 10/01/2009 - "RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested). " 02/01/1992 - "In particular the evaluation of serum CA19.9 or CA72.4 could be very useful in the monitoring of patients with mucinous ovarian cancer, which often fails to express CA125 antigen." 12/01/2008 - "This study was to investigate the safety and efficacy of using 6B11mini as an antigen to treat ovarian cancer. " 05/20/2009 - "Through the studies of the cell receptor and immunity-associated genes we expect to identify the molecular biology index of ovarian cancer-associated antigens." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 04/01/2007 - "BACKGROUND & OBJECTIVE: The most effective treatment for epithelial ovarian cancer is the combination of surgical operation and chemotherapy. " 06/01/2004 - "CONCLUSION: Radical surgery associated with early postoperative chemotherapy followed by systemic chemotherapy in the treatment of ovarian cancer makes it possible to achieve the best survival results and long periods of disease free." 01/01/2002 - "BACKGROUND: While most patients with advanced ovarian cancer can achieve prolonged remission with surgery and chemotherapy, eventually most will recur. " 01/01/2000 - "To investigate the best first-line chemotherapy regimen for the treatment of advanced epithelial ovarian cancer (AEOC), the efficacy of three chemotherapy regimens for treatment of the patients with AEOC in our hospital during Jan. " 11/01/1992 - "The results of the neurophysiologic examinations performed before and immediately after chemotherapy suggest that these schedules besides being safe and effective in the treatment of the ovarian cancer, have an extremely low peripheral neurotoxicity." Order ALL the reference details at left...
2.	Heterologous Transplantation (Xenotransplantation) 10/01/2006 - "CONCLUSION: This new xenograft model accompanied by noninvasive imaging is highly reproducible and likely to be very useful in testing new treatment strategies for ovarian cancer." 01/01/2005 - "Results indicated significant growth inhibitory activity of the transgenic factor in a human umbilical vein endothelial cell proliferation assay in vitro and protection against the growth of an angiogenesis-dependent human ovarian cancer cell line, SKOV3.ip1, xenograft in vivo with increased disease-free survival. " 03/01/2006 - "Further, therapeutic efficacy was evaluated in vivo using human ovarian cancer xenograft mouse models. " 01/01/1998 - "We have investigated whether [186Re]-labeled chimeric monoclonal antibody 323/A3 (MAb c-323/A3) is as effective as [186Re]-labeled mouse 323/A3 (m-323/A3) in the growth inhibition of human ovarian cancer xenografts OVCAR-3 and FMa. " 02/01/1992 - "Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model." Order ALL the reference details at left...
3.	Combination Drug Therapy (Combination Chemotherapy) 07/01/1995 - "The best treatment results for advanced-stage ovarian cancer patients are obtained with cytoreductive surgery followed by combination chemotherapy. " 04/01/2001 - "Cytoreductive surgery followed by combination chemotherapy results in an approximately 75% complete remission rate in patients with advanced ovarian cancer. " 12/01/1991 - "Adjuvant combination chemotherapy is beneficial for selected patients with early-stage ovarian cancer who are at high risk for failure after surgical treatment alone." 07/15/1983 - "We conclude that this four-drug regimen is effective in the treatment of relapsing ovarian cancer patients and should be considered for study as a front-line combination chemotherapy for previously untreated patients." 06/01/2004 - "This chemotherapy combination appears effective for epithelial ovarian cancer." Order ALL the reference details at left...
4.	Laparotomy 07/01/2000 - "About 40 years ago, second-look laparotomy (SLL) was introduced to evaluate, surgically and pathologically, primary treatment in case a clinical complete remission was obtained in ovarian cancer patients. " 01/01/2000 - "MATERIAL AND METHODS: Having observed complete clinical remission in 356 patients with ovarian cancer, second-look laparotomy was performed. " 02/01/1994 - "In conclusion, IPC-CT could be very effective in monitoring response to treatment and could markedly reduce the number of ovarian cancer patients requiring second-look laparotomy." 05/03/1986 - "Complete remission at laparotomy: still a gold standard in ovarian cancer?" 01/01/1985 - "The histopathological findings at second-look laparotomy in 20 patients with complete clinical remission of epithelial ovarian cancer were compared with the findings at preoperative ultrasound (US) examination. " Order ALL the reference details at left...
5.	Radioimmunotherapy 07/01/1997 - "CONCLUSIONS: The favorable physical characteristics of 186Re as well as its efficacy when conjugated to a MAb indicate 186Re as an attractive radionuclide in radioimmunotherapy of ovarian cancer patients." 01/01/2010 - "The aim of this study was to investigate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice using different fractionated treatment regimens. " 08/01/2009 - "PURPOSE: The aim of this study was to investigate the therapeutic efficacy of the alpha-radioimmunotherapy of ovarian cancer in mice, using different specific activities. " 11/01/2006 - "OBJECTIVE: The aim of this study was to investigate the therapeutic efficacy and myelotoxicity during fractionated radioimmunotherapy of ovarian cancer in mice. " 11/15/2006 - "PURPOSE: To elucidate the therapeutic efficacy of alpha-radioimmunotherapy of ovarian cancer in mice. " Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Ovarian Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 966 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>